Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
Status:
Not yet recruiting
Trial end date:
2037-12-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and
efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1
(PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with
relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard
frontline therapy.